WO2005028500A1 - 生体成分の組成が変化した溶液の調整方法 - Google Patents
生体成分の組成が変化した溶液の調整方法 Download PDFInfo
- Publication number
- WO2005028500A1 WO2005028500A1 PCT/JP2004/012923 JP2004012923W WO2005028500A1 WO 2005028500 A1 WO2005028500 A1 WO 2005028500A1 JP 2004012923 W JP2004012923 W JP 2004012923W WO 2005028500 A1 WO2005028500 A1 WO 2005028500A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solution
- preparing
- biological component
- protein
- module
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 101
- 239000000203 mixture Substances 0.000 title claims description 70
- 239000000243 solution Substances 0.000 claims abstract description 300
- 239000012528 membrane Substances 0.000 claims abstract description 261
- 238000000926 separation method Methods 0.000 claims abstract description 165
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 155
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 152
- 108010088751 Albumins Proteins 0.000 claims abstract description 98
- 102000009027 Albumins Human genes 0.000 claims abstract description 98
- 239000007788 liquid Substances 0.000 claims abstract description 94
- 238000004458 analytical method Methods 0.000 claims abstract description 42
- 238000001962 electrophoresis Methods 0.000 claims abstract description 18
- 238000004811 liquid chromatography Methods 0.000 claims abstract description 8
- 239000012466 permeate Substances 0.000 claims abstract description 8
- 210000002966 serum Anatomy 0.000 claims description 55
- 239000011550 stock solution Substances 0.000 claims description 53
- 241000282414 Homo sapiens Species 0.000 claims description 38
- 239000000463 material Substances 0.000 claims description 38
- 108010026552 Proteome Proteins 0.000 claims description 29
- -1 polyethylene Polymers 0.000 claims description 29
- 239000000126 substance Substances 0.000 claims description 24
- 229920002492 poly(sulfone) Polymers 0.000 claims description 21
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 20
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 19
- 239000008280 blood Substances 0.000 claims description 19
- 239000007864 aqueous solution Substances 0.000 claims description 17
- 239000003085 diluting agent Substances 0.000 claims description 16
- 210000002381 plasma Anatomy 0.000 claims description 16
- 239000004698 Polyethylene Substances 0.000 claims description 14
- 229920000573 polyethylene Polymers 0.000 claims description 14
- 239000004743 Polypropylene Substances 0.000 claims description 13
- 239000001913 cellulose Substances 0.000 claims description 13
- 239000002808 molecular sieve Substances 0.000 claims description 13
- 229920001155 polypropylene Polymers 0.000 claims description 13
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 13
- 239000004952 Polyamide Substances 0.000 claims description 12
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 12
- 229920002647 polyamide Polymers 0.000 claims description 12
- 229920000515 polycarbonate Polymers 0.000 claims description 12
- 239000004417 polycarbonate Substances 0.000 claims description 12
- 229920002678 cellulose Polymers 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 10
- 229920000058 polyacrylate Polymers 0.000 claims description 10
- 229920000728 polyester Polymers 0.000 claims description 10
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 10
- 210000002700 urine Anatomy 0.000 claims description 10
- 229920002301 cellulose acetate Polymers 0.000 claims description 9
- 229920000193 polymethacrylate Polymers 0.000 claims description 9
- 239000002033 PVDF binder Substances 0.000 claims description 8
- 229920002873 Polyethylenimine Polymers 0.000 claims description 8
- 239000001045 blue dye Substances 0.000 claims description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 7
- 239000004793 Polystyrene Substances 0.000 claims description 7
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 7
- 235000013824 polyphenols Nutrition 0.000 claims description 7
- 229920002223 polystyrene Polymers 0.000 claims description 7
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 claims description 6
- 206010003445 Ascites Diseases 0.000 claims description 6
- 208000002151 Pleural effusion Diseases 0.000 claims description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 6
- 238000004949 mass spectrometry Methods 0.000 claims description 6
- 239000002504 physiological saline solution Substances 0.000 claims description 6
- 210000003296 saliva Anatomy 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 5
- 210000001138 tear Anatomy 0.000 claims description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 4
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 4
- 230000003196 chaotropic effect Effects 0.000 claims description 4
- 229920002635 polyurethane Polymers 0.000 claims description 4
- 239000004814 polyurethane Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 102000007327 Protamines Human genes 0.000 claims description 3
- 108010007568 Protamines Proteins 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 229950008679 protamine sulfate Drugs 0.000 claims description 3
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 238000010790 dilution Methods 0.000 abstract 1
- 239000012895 dilution Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 131
- 239000012510 hollow fiber Substances 0.000 description 69
- 238000005194 fractionation Methods 0.000 description 24
- 238000011084 recovery Methods 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000000706 filtrate Substances 0.000 description 19
- 238000012545 processing Methods 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- 238000001914 filtration Methods 0.000 description 16
- 229920001296 polysiloxane Polymers 0.000 description 16
- 230000002209 hydrophobic effect Effects 0.000 description 15
- 238000001179 sorption measurement Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 12
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 229920001477 hydrophilic polymer Polymers 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 229920001600 hydrophobic polymer Polymers 0.000 description 8
- 230000002572 peristaltic effect Effects 0.000 description 8
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000005070 sampling Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000004695 Polyether sulfone Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 229920006393 polyether sulfone Polymers 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 229920002284 Cellulose triacetate Polymers 0.000 description 4
- 239000004593 Epoxy Substances 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 4
- 229920003174 cellulose-based polymer Polymers 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000004382 potting Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 235000004252 protein component Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 4
- 102000003966 Alpha-1-microglobulin Human genes 0.000 description 3
- 101800001761 Alpha-1-microglobulin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 125000001165 hydrophobic group Chemical group 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 239000012146 running buffer Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002834 transmittance Methods 0.000 description 3
- ZAMLGGRVTAXBHI-UHFFFAOYSA-N 3-(4-bromophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(CC(O)=O)C1=CC=C(Br)C=C1 ZAMLGGRVTAXBHI-UHFFFAOYSA-N 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- 101710150365 Albumin-1 Proteins 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 125000005396 acrylic acid ester group Chemical group 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000005660 hydrophilic surface Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 231100000647 material safety data sheet Toxicity 0.000 description 2
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920002620 polyvinyl fluoride Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000010206 sensitivity analysis Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- ACERFIHBIWMFOR-UHFFFAOYSA-N 2-hydroxy-3-[(1-hydroxy-2-methylpropan-2-yl)azaniumyl]propane-1-sulfonate Chemical compound OCC(C)(C)NCC(O)CS(O)(=O)=O ACERFIHBIWMFOR-UHFFFAOYSA-N 0.000 description 1
- LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- INEWUCPYEUEQTN-UHFFFAOYSA-N 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CNC1CCCCC1 INEWUCPYEUEQTN-UHFFFAOYSA-N 0.000 description 1
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
- RZQXOGQSPBYUKH-UHFFFAOYSA-N 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCC(CO)(CO)NCC(O)CS(O)(=O)=O RZQXOGQSPBYUKH-UHFFFAOYSA-N 0.000 description 1
- XCBLFURAFHFFJF-UHFFFAOYSA-N 3-[bis(2-hydroxyethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCCN(CCO)CC(O)CS(O)(=O)=O XCBLFURAFHFFJF-UHFFFAOYSA-N 0.000 description 1
- XNPKNHHFCKSMRV-UHFFFAOYSA-N 4-(cyclohexylamino)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCNC1CCCCC1 XNPKNHHFCKSMRV-UHFFFAOYSA-N 0.000 description 1
- VTOWJTPBPWTSMK-UHFFFAOYSA-N 4-morpholin-4-ylbutane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCN1CCOCC1 VTOWJTPBPWTSMK-UHFFFAOYSA-N 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- 239000007988 ADA buffer Substances 0.000 description 1
- 101150035093 AMPD gene Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108700016232 Arg(2)-Sar(4)- dermorphin (1-4) Proteins 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 239000007992 BES buffer Substances 0.000 description 1
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 1
- 239000008000 CHES buffer Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- GIZQLVPDAOBAFN-UHFFFAOYSA-N HEPPSO Chemical compound OCCN1CCN(CC(O)CS(O)(=O)=O)CC1 GIZQLVPDAOBAFN-UHFFFAOYSA-N 0.000 description 1
- 102000014702 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- GYCMBHHDWRMZGG-UHFFFAOYSA-N Methylacrylonitrile Chemical compound CC(=C)C#N GYCMBHHDWRMZGG-UHFFFAOYSA-N 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 description 1
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- JQYMGXZJTCOARG-UHFFFAOYSA-N Reactive blue 2 Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S(O)(=O)=O)=C1 JQYMGXZJTCOARG-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 231100000987 absorbed dose Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ACJOYTKWHPEIHW-UHFFFAOYSA-N ethyl 3-phenylprop-2-ynoate Chemical compound CCOC(=O)C#CC1=CC=CC=C1 ACJOYTKWHPEIHW-UHFFFAOYSA-N 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 238000012946 outsourcing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
- B01D63/021—Manufacturing thereof
- B01D63/022—Encapsulating hollow fibres
- B01D63/0222—Encapsulating hollow fibres using centrifugal forces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/02—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4005—Concentrating samples by transferring a selected component through a membrane
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4005—Concentrating samples by transferring a selected component through a membrane
- G01N2001/4016—Concentrating samples by transferring a selected component through a membrane being a selective membrane, e.g. dialysis or osmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
Definitions
- the present invention relates to a method and apparatus for preparing a solution in which the composition of a biological component is changed by separating biological molecules such as proteins from a biological component-containing solution, particularly human plasma, urine, or the like.
- the present invention relates to a method and apparatus for preparing a solution in which the composition of a biological component is changed by removing components that interfere with the detection of trace components, in particular, high molecular weight proteins, for the purpose of clinical proteome analysis.
- proteome analysis research has begun to attract attention as a post-genome study. Since the gene product protein is considered to be more directly linked to the pathology of the disease than the gene, the results of proteome analysis that comprehensively examines the protein are expected to be widely applicable to diagnosis and treatment. There is a high possibility that many pathogenic proteins and disease-related factors that could not be discovered by genome analysis can be discovered.
- MALDI-TOF-Mb matrix assisted laser desorption ionization time—of—flignt mass spectrometry
- high-throughput ultra-low-volume dispensing of polypeptides becomes possible, and even to the very small amount of powerful proteins that can be detected conventionally. Has become identifiable and has become a powerful tool for searching for disease-related factors.
- Biomarkers behave in relation to disease states, so they can be diagnostic markers and are also likely to be drug discovery targets. In other words, since the results of proteome analysis are more likely to be diagnostic markers and drug targets than specific genes, they will be a trump card in the diagnosis and treatment of the post-genome era, and the identified biomarkers will be used in patients' drug response. V, a major promotion of tailor-made medicine It can play a role.
- Human proteins are estimated to have more than 100,000 species. It is said that only 10,000 proteins are contained in serum, and the total serum concentration is about 60-8 Omg / mL. is there. Proteins with high contents in human serum include albumin (molecular weight 66 kDa), immunoglobulin (150-190 kDa), transferrin (80 kDa), haptoglobin (> 85 kDa), lipoprotein (several lOOkDa), etc. It is present in large quantities in excess of / mL.
- bioactive proteins such as peptide hormones, interleukins, and cytokins, which are considered to be biomarkers of pathological conditions and etiological factors, are present only in extremely small amounts of less than Ing / mL.
- the content ratio is in the nano to pico level compared to the high content component of the polymer.
- 70% or less of all types of proteins have a molecular weight of 60,000 (60 kDa) or less, and most of the aforementioned trace biomarker proteins are mostly included in this region (for example, Non-patent document 1). Since these proteins pass through the kidneys and are partially excreted in urine, it is possible to measure urine as well as blood as a sample.
- Proteome analysis by general serologic tests requires detection of pathogen-related trace components.
- MALD TOF—MS and ES tom MS electrospray ionization mass spectrometry
- a product that has already been put into practical use or a disclosed technique includes a carrier on which an affinity ligand such as a blue dye is immobilized. ), A centrifugal tube-type device that separates high molecular weight components by centrifugal filtration (commercialized), a method of fractionation by the electrophoresis principle, a traditional precipitation method such as Cohn's ethanol precipitation, etc. There is a method of fractionation by chromatography (for example, Non-Patent Document 2).
- proteome analysis will be widely performed in medical research and clinical settings, and faster and more accurate examinations and diagnoses will be possible. It is expected to be a powerful tool for investigating the cause of early intractable diseases and developing early diagnostic methods.
- the required conditions for the technique include the ability to flow plasma components at high speed, no protein denaturing action, and fine processing for high functionality. And it is not very expensive. We have not found any devices or devices that can solve these issues.
- Non-patent Document 1 By Anderson 'NL (Anderson NL), Anderson' NG (Anderson NG), "The Human 'Plasma Proteome: History ⁇ ⁇ ⁇ Character ⁇ ⁇ ⁇ And” Diagnos Aitsk “Bros. plasma & proteome: history, character, and diagnostic prospects), Molecular & Cellular Proteomics, (USA), The American American Society for Biochemistry, and Molecular Molecular Biology 'Incorporated (The American Society for Biochemistry and Molecular Biology, Inc.), 2002, Volume 1, p845-867.
- Non-patent Document 2 The Society of Biochemistry, Japan, “Lecture on Experimental Chemistry (Vol.1) Protein (1) Isolation, Purification, Properties”, Tokyo Chemical Dojin, 1990
- Non-patent Document 3 Cell Engineering Separate Volume, "Bio-Experiment Illustrated 5", Shujunsha, 2001
- Non-patent Document 4 N. Ahmed et al, Proteomics, Online Edition, June 23, 2003
- Non-patent Document 5 D. Shi Rothemund et al. (2003), Proteomics, Vol. 3, pp. 279-287)
- Patent Document 1 Japanese Patent Publication No. 2002-542163
- Patent Document 2 Japan, Patent No. 3297707
- the problem to be solved by the present invention is to advantageously separate and remove extra high molecular weight proteins from a solution containing a biological component, which are obstructive when performing clinical proteome analysis.
- An object of the present invention is to provide a method and an apparatus for preparing a biological component-containing solution in which the composition of a biological component is changed, which is suitable for proteome analysis.
- the first invention group includes the following inventions.
- Concentration composition of albumin relative to total protein characterized in that a biological component-containing solution is supplied to a separation membrane having a transmission ratio of at least ⁇ 2-microglobulin and albumin of 50 or more and permeated by the separation membrane.
- composition ratio of j82-microglobulin in the total protein of the solution in which the composition of the biological component has changed should be at least 10 times the composition ratio of j82-microglobulin in the total protein of the solution containing the biological component.
- the biochemical component is characterized in that the biological component is blood, plasma, serum or other blood-derived material, urine, ascites, saliva, tears, cerebrospinal fluid, pleural effusion, or a solution obtained by extracting protein from cellular power. How to prepare these solutions,
- a method for analyzing a protein contained in a biological component comprising preparing a solution in which the composition of the biological component has been changed by any one of the above methods, and then analyzing the protein contained in the solution.
- the method for analyzing a protein according to claim 9, wherein the means for analyzing the protein is at least one selected from mass spectrometry, electrophoresis analysis and liquid chromatography.
- a device having a module with a built-in separation membrane having a permeation ratio of ⁇ 2-microglobulin and albumin of 50 or more, wherein the module is provided on the stock solution side of the separation membrane by the stock solution inlet for the biological component-containing solution and the separation membrane.
- a second invention group includes the following inventions.
- a module having a built-in separation membrane, a stock solution inlet and a stock solution outlet connected to the stock solution side flow path of the separation membrane, and a permeate outlet of the separation membrane;
- a solution circulation circuit that connects the undiluted solution inlet and the undiluted solution outlet, and has a pump and a target liquid inlet for separation on the way;
- a diluent inlet provided at a position upstream of the target liquid inlet for separation or at a position in the middle of the solution circulation circuit;
- a liquid flow circuit for preparing a solution in which the composition of the biological component has been changed comprising:
- At least two liquid flow circuits are included, and a liquid outlet to be separated of one liquid flow circuit and a liquid inlet to be separated of another liquid flow circuit are directly or indirectly connected by a liquid flow path.
- a biological component-containing solution was flowed into the stock solution side of the separation membrane, and the solution on the stock solution side was circulated through a solution circulation circuit provided outside the module, and passed through the separation membrane.
- This is a step of taking out the liquid as a solution having a changed composition of the biological component, and after starting the flow of the biological component-containing solution, diluting the biological component-containing solution with the module.
- a method for preparing a solution having a changed composition of a biological component characterized by additionally flowing the solution into the stock solution side of a separation membrane incorporated in the
- the biological component is a solution obtained by extracting blood-derived substances such as blood, serum, urine, ascites, saliva, tears, cerebrospinal fluid, pleural effusion, or cellular protein. How to prepare the solution,
- the method is characterized by using two modules, using the solution obtained by any of the above-mentioned preparation methods in the first module, and performing the above-mentioned preparation method in the second module.
- the third invention group includes the following inventions.
- a method for preparing a solution having a changed composition of a biological component from a biological component-containing solution by performing at least two steps of treatment on the biological component-containing solution wherein the step includes:
- step (1) add cellulose, cellulose acetate, polycarbonate, Materials containing at least one material selected from the group consisting of polyethylene, polymethacrylate, polyacrylate, polyamide, polyvinylidene fluoride, polyacrylonitrile, polyester, polyurethane, polystyrene, polyethylene and polypropylene.
- a method for preparing the solution characterized by using
- cellulose, cellulose acetate, polycarbonate, polysulfone, polymethacrylate, polyacrylate, polyamide, polyvinyl fluoride, polyacrylonitrile, polyester, polyethylene and polypropylene are also used.
- the strength of cellulose, cellulose acetate, polycarbonate, polysulfone, polymethacrylate, polyacrylate, polyamide, polyvinyl fluoride, polyacrylonitrile, polyethylene and polypropylene is also selected.
- FIG. 1 is a schematic diagram of a separation system used in Examples 1 and 3 of the present invention. (1 membrane separation unit)
- FIG. 2 is a conceptual diagram of a separation system used in Embodiment 2 of the present invention. (2 membrane separation units)
- FIG. 3 is a schematic diagram of a separation system used in Example 4 of the present invention. (3 membrane separation units)
- FIG. 4 is a schematic diagram of a system used in Examples 5 and 6 of the present invention. (Example of three units with membrane separation function and adsorption function and one concentration unit)
- FIG. 5 is a conceptual diagram showing an example of a device belonging to a group of the third invention.
- FIG. 6 is an electrophoretic photograph of a solution in which the composition of a biological component has changed.
- FIG. 7 is a two-dimensional electrophoretic photograph of the solution in which the composition of the biological component obtained in Example 2 has changed.
- FIG. 8 is a two-dimensional electrophoresis photograph of a human serum solution.
- the solution in which the composition of the biological component is changed is a solution derived from a living body such as blood, that is, a solution containing the biological component, which is subjected to a specific treatment as a stock solution and subjected to a specific treatment. It is a solution in which is changed.
- blood refers to animal blood such as human beings, and also includes solutions such as serum and plasma that are a part of components of blood.
- solution derived from a living body includes, for example, a solution containing a protein in a biological substance such as a solution obtained by extracting protein from at least blood, urine, saliva, tears, cerebrospinal fluid, ascites, pleural effusion, or cells. Is done.
- the “separation membrane module” referred to in the present invention is one in which a separation membrane is housed in a housing.
- the housing is provided with an inlet for the solution to be separated and an outlet for the solution, and a permeate outlet for the solution separated through the separation membrane and flowing out.
- the material of the housing is not particularly limited, but examples thereof include plastic materials such as polycarbonate, polypropylene, polystyrene, polysulfone, and polyethersulfone.
- the solution in which the composition of the biological component-containing solution obtained in the present invention has changed is preferably used for protein analysis, particularly for proteome analysis.
- the analysis method is not particularly limited, and examples thereof include LC, 2D-PAGE, nuclear magnetic resonance (NMR), MALDI-TOF-MS, and ESI-MS. These are analysis methods in which the analysis sensitivity is reduced due to the high content of proteins present in a large amount in some solutions such as albumin, and by using the solution obtained in the present invention. , High sensitivity analysis becomes possible. It is also useful for proteome analysis using MS and electrophoresis.
- the MS to which the solution preparation apparatus of the present invention can be directly or indirectly connected is not particularly limited, but is preferably an electrospray ionization type, an atmospheric pressure ionization type, a quadrupole (QQQ) type, or a magnetic sector type. , Time-of-flight, MS / MS, MSn, FT-MS, ion trapping and combinations thereof. Also includes tandem MS such as MSZ MS or MSn (eg, MS3). In the case of tandem MS, all types of MS are applicable Forces especially for ion trapping, quadrupole-one-time-of-flight (Q-TOF), FT-MS, and sector-one instruments with quadrupole and ion-trapping Using a combination is more efficient.
- the biological component-containing solution is converted to j8-microglobulin.
- the sieve is supplied to a separation membrane having a permeability ratio of 50 or more, which is a value obtained by dividing the coefficient by the albumin sieve! / Coefficient, and the liquid permeated through the separation membrane is collected.
- a module having a built-in separation membrane having a permeation ratio of j82-microglobulin and albumin of 50 or more is provided, and the module is provided on the stock solution side of the separation membrane with a stock solution inlet for a biological component-containing solution, An apparatus having at least an outlet for the permeated liquid permeated by the separation membrane is used.
- a stock solution outlet for a biological component-containing solution may be provided on the stock solution side of the separation membrane.
- the permeation ratio of the separation membrane is preferably 70 or more, and more preferably 140 or more. There is no particular upper limit, but in a membrane separation unit having this value that is too high, the desired Since there is a concern that the amount of recovering a protein having a molecular weight of less than 150,000 will be reduced, it is preferably 10000 or less. It is preferable to use a hollow fiber membrane for this separation membrane. Hollow fiber membranes have been widely used as materials for dialysis modules called artificial kidneys for the purpose of transmitting proteins. The separation membrane used in the artificial kidney is designed to prevent proteins such as albumin from permeating as much as possible, and to transmit low molecular components such as creatine and urea.
- Blood is purified by flowing out low-molecular proteins unnecessary for living organisms from the outer cavity of the hollow fiber.
- a method of permeating the hollow fiber from the lumen side to the outside through the hollow fiber membrane is preferable.
- the present invention can be carried out efficiently because it is easy to increase the surface area and the pressure loss during operation is small.
- the material of the separation membrane used in the group of the first invention is not particularly limited, but may be a cellulose-based polymer such as cellulose or cellulose-triacetate, a polysulfone-based polymer such as polycarbonate, polysulfone or polyethersulfone, or a polymethylmethalate.
- Polymethacrylates such as acrylates, polyacrylates, polyamides, poly (vinylidene fluoride), polyacrylonitrile, polyesters, polyethylene and polypropylene.
- polysulfone which is often used in dialysis machines in recent years, is a preferable material because of its good fractionation characteristics.
- the flow path in the membrane of the separation membrane is an asymmetric structure, and furthermore, an asymmetric structure with a multilayer structure consisting of a dense layer and a support layer with high porosity and maintaining membrane strength. It is preferable that This asymmetric structure is judged by observing the cross-sectional structure of the film under an observation condition of 1000 times using an electron microscope. Judgment is made based on whether there are both a layer in which vacancies cannot be sufficiently confirmed and a layer in which vacancies can be confirmed in the thickness direction of the film. If both layers are confirmed, the structure is identified as asymmetric.
- the pores near the surface in contact with the undiluted solution be the densest. This is also a force capable of reducing clogging of the film surface due to the solute.
- the separation membrane used in the group of the first invention does not adsorb proteins as much as possible.
- a membrane having a hydrophilic surface is preferable.
- hydrophilic membranes have the effect of suppressing protein adsorption, which gives important information for proteome analysis, and recovering them without waste.
- the hydrophilic film is not particularly limited as long as it is hydrophilized, but may be a film obtained by copolymerizing a hydrophilic monomer and a hydrophobic monomer, or a hydrophilic polymer and a hydrophobic polymer.
- hydrophilic polymer bonded to and adhered to the surface of a hydrophobic polymer film, or a hydrophobic polymer surface that is also made of a hydrophobic polymer. And those subjected to radiation treatment.
- the chemical structure for providing the hydrophilic component is not particularly limited, but hydrophilic polymers such as polyalkylene oxides such as polyethylene glycol, polybutylpyrrolidone, polybutyl alcohol, polyhydroxyethyl methacrylate, and polyatarylamide are preferred.
- a step of removing the solvent such as hydraulic water or the like obtained by permeation through the separation membrane may be further performed to concentrate the protein.
- a separation membrane such as a flat filter or a hollow fiber membrane having a molecular sieve effect is used to perform concentration by a separation sieve.
- a separation membrane such as a flat filter or a hollow fiber membrane having a molecular sieve effect is used to perform concentration by a separation sieve.
- the material of the membrane that can be used in the concentration step is not particularly limited, but may be cellulose, a cellulose-based polymer such as cellulose triacetate or the like, a polycarbonate, a polysulfone-based polymer such as polysulfone-polyethersulfone, or a polymethyl sulfonate.
- Materials containing polymers selected from the group consisting of polymethacrylic acid esters such as methacrylate, polyacrylic acid esters, polyamides, polyvinylidene fluoride, polyacrylonitrile, polyester, polyethylene and polypropylene are also used. .
- polysulfone which is widely used in recent years for dialysis machines and the like, is a preferable material because it can obtain a membrane having fractionation characteristics and high water permeability.
- an asymmetric structure having a sponge structure close to a uniform structure and a multilayer structure of a dense layer and a support layer having a high porosity and maintaining the film strength are also provided. Any of the membranes can be used.
- the molecular fractionation performance of the membrane used in the concentration step the molecular fractionation ability is such that the peptide does not pass through physiological saline, for example, the cut-off value is 0.5 kDa or less, preferably 0.1 kDa or less. It is preferable to use a high-performance membrane or ultrafiltration membrane!
- composition of j82-microglobulin in the total protein of the biological component-containing solution is preferably at least 10 times, more preferably at least 100 times, particularly preferably at least 1,000 times. This is because in a mass spectrometer or the like, the amount of protein that can be injected into the device is limited, so that the measurement sensitivity can be increased.
- composition ratio of albumin in the protein is 0. Desirably less than 3, more preferably less than 0.1, or even less than 0.01! /.
- FIG. 1 is a conceptual diagram showing an example of an apparatus for preparing the solution of the first invention.
- the flow of the liquid is indicated by arrows.
- a sample which is a biological component such as serum, or a biological component-containing solution containing the same is supplied from a pump for injection 100 through a three-way valve 101 to a first separation membrane module having a built-in separation membrane having a specific permeability in the first step.
- the solution is injected into 105 and is sent through a solution circulation circuit 102 composed of a tube by a circulation pump 103 to circulate.
- the permeate that has passed through the separation membrane in the first step is obtained from the first-stage membrane unit treatment liquid recovery port 104, which is the outlet of the permeate.
- This embodiment is a basic unit (unit) of one process. As a result, a desired proteome analysis liquid is obtained. If further removal of high molecular weight proteins is desired, multiple modules can be connected.
- FIG. 2 shows an example in which two modules are connected to perform two-stage processing
- FIG. 3 shows an example in which three modules are connected to perform three-stage processing.
- the permeated liquid is injected into the unit of the next step by a tube directly connected to the processing liquid recovery port of the membrane separation unit which is the permeated liquid outlet.
- the target solution is supplied to the recovery port (104 in the apparatus shown in FIG. 1, 204 in the apparatus shown in FIG. 2, and 304 in the apparatus shown in FIG. 3) in the most downstream unit of the process. can get.
- FIG. 4 shows an apparatus in which a module having a function of concentrating is further connected to the apparatus shown in FIG. 3, and a target solution is recovered from a processing solution recovery port 407 of the concentrating unit.
- a module containing a separation membrane is used, and the solution containing the biological component is caused to flow into the undiluted solution side of the separation membrane. Circulating the liquid on the side through a solution circulation circuit provided outside the module to remove the solution that has passed through the separation membrane. After the biological component-containing solution flows in, a diluent for the biological component-containing solution is supplied to the module. It is characterized by additional flow into the stock solution side of the built-in separation membrane.
- a stock solution inlet and a stock solution outlet having a built-in separation membrane and connected to a stock solution side channel of the separation membrane, and a separation solution are provided.
- a module having an outlet for the permeate of the membrane, a solution circulation circuit connecting the undiluted solution inlet and the undiluted solution outlet, and having a pump and a separation target liquid inlet on the way, and a position upstream of the separation target liquid inlet Or a diluent inlet provided at a position in the middle of the solution circulation circuit.
- the separation membrane is a porous separation membrane, and may be any of a flat membrane type separation membrane such as a flat filter, a cartridge type filter, and a hollow separation membrane such as a hollow fiber membrane. Can also be used.
- hollow fiber membranes can be used efficiently because the membrane surface area per treatment liquid volume is large and pressure loss can be reduced.
- the inner diameter of the hollow fiber membrane is preferably smaller, more preferably 1000 m or less, more preferably 500 / zm or less.
- the flat filter has an advantage that it can be easily formed at a low cost.
- the membrane material examples include cellulose, cellulose acetate, polycarbonate, polysulfone, polymethacrylates such as polymethyl methacrylate, polyacrylate, polyamide, polyvinylidene fluoride, polyacrylonitrile, polyester, polyethylene and polyethylene.
- polypropylene and derivatives thereof One or more materials selected from the group consisting of polypropylene and derivatives thereof can also be exemplified.
- polysulfone which is often used in dialysers in recent years, is preferred because of its good fractionation characteristics!
- the separation membrane used in the group of the second invention it is preferable to use a separation membrane having a permeation ratio of 50 or more between a protein having a molecular weight of less than 150,000 and a protein having a molecular weight of 60,000 or more.
- Other preferable characteristics and shapes are the same as those of the separation membrane of the first invention group. The same as described.
- the biological component-containing solution is caused to flow into the undiluted solution side of the separation membrane, and then the diluent for the biological component-containing solution is caused to flow. This is because, when the diluent is added, excessive concentration on the surface of the membrane is prevented, and the permeation ratio of the separation membrane is prevented. Further, it is preferable to use a physiological saline or a "buffer solution" as the diluting solution.
- Buffer solution includes MES, BIS-TRIS, ADA, ACES, PIPES, MOPSO, BIS-TRIS PROPANE, BES, MOPS, TES, HE PES, DIPSO, MOBS, TAPSO, TRIZMA, HEPPSO, POPSO, TEA, EPP S, TRICINE, GLY—GLY, BICINE, PBS, TAPS, AMPD, TABS, AMPSO, CHES, CAPSO, AMP, CAPS, CABS and the like.
- the above buffer solutions are abbreviated, but the details can be understood by referring to the catalogs of reagent manufacturers such as Wako Pure Chemical Industries, Ltd., Sigma-Aldrich Japan Co., Ltd. and MSDS (Safety Data Sheet). .
- the flow rate Q1 of the biological component-containing solution flowing into the module is the flow rate of the liquid flowing into the module and flowing through the circuit, and is preferably larger than the flow rate Q2 at which the separated liquid is sent. This is because it is also effective in preventing concentration on the surface of the separation membrane, preventing accumulation of deposits on the membrane surface, and preventing clogging of the membrane pores. Further, it is desirable that the ratio Q2ZQ1 of the flow rate Q1 of the liquid flowing into the separation membrane module and the flow rate Q2 of the separated liquid to be sent be 0.5 or less. When the flow rate Q1 of the liquid flowing into the separation membrane module and the flow rate Q2 at which the separated liquid is sent Q2ZQ1 is 0, filtration is not performed and mass transfer only by diffusion is performed. Since the speed becomes slow, it is desirable that the speed is 0.005 or more.
- the flow rate Q2 permeating through the separation membrane and the flow rate Q3 of the diluent flowing into the module have a relationship of 0.5 ⁇ Q2 / Q3 ⁇ 1.5. 9-1. 1, that is, preferably about 1.
- two modules are prepared, and in the first module, while a diluent is additionally introduced as described above, a solution in which the composition of the biological component is changed is obtained.
- a solution in which the composition of the biological component is changed is obtained.
- a high-molecular-weight tank more suitable for proteome analysis The solution from which the protein has been removed can be prepared.
- additional modules such as third and fourth modules can be prepared and similar steps can be performed.
- a solution containing a large amount of the target protein component can be obtained. It can be efficiently prepared.
- an apparatus for preparing a solution having a changed composition from a biological component-containing solution in the group of the third invention (1) means for adsorbing a part or the whole of a protein having a molecular weight of albumin or more, 2) a means for fractionating a part or all of a protein having a molecular weight of albumin or more by a molecular sieve, and (3) a means for concentrating the protein. It is characterized in that they are connected by a channel. It is preferable that the apparatus has a solution outflow path that can be connected to a liquid chromatograph, an electrophoresis apparatus, or a mass spectrometer.
- albumin which is a molecular weight standard, refers to albumin derived from humans, pests, other mammals and birds, and is determined by the target organism.
- the albumin is used as a reference.
- a protein having a molecular weight of albumin or higher mainly refers to a protein having a higher molecular weight than albumin (molecular weight of 60 to 70,000). Whether it has a higher molecular weight than albumin is determined by SDS-PAGE ( sodium dodecylsulphate-polyacrylamide gel electrophoresis).
- the term “adsorption” means that the protein is soluble in an aqueous solution and is captured by the substance due to the interaction with the substance present in the process.
- the material used for the adsorption in this step is not particularly limited, but may be a cellulose-based polymer such as cellulose or cellulose triacetate, a polysulfone-based polymer such as polycarbonate, polysnoreon, or polyetherenosulfone, or a polymethacrylic acid such as polymethyl methacrylate. Ester, polyacrylate, polyamide, polyvinylidene fluoride, polyacrylonitrile, polyester, polyurethane, polystyrene, polyethylene, and polypropylene are used.
- the shape of the material may be spherical beads or fibers, flat fibers such as long fibers or short fibers, and knitted, woven or non-woven fabrics, or hollow.
- a shape having a large surface irregularity is preferable for the effect of increasing the adsorption surface area.
- a permeation type separation membrane such as a flat membrane or a hollow fiber membrane is preferable because low molecular weight proteins can be separated at the same time.
- the properties of the base material itself are necessary and desired to be removed from the target solution.
- the base material include a material whose surface is made hydrophilic so that low molecular weight proteins are not adsorbed, albumin and the like.
- a material having a hydrophobic property is appropriately selected and used.
- the substrate having a hydrophilic surface may be a substrate obtained by copolymerizing a hydrophilic monomer and a hydrophobic monomer, or a substrate obtained by mixing a hydrophilic polymer and a hydrophobic polymer.
- a surface obtained by bonding and attaching a hydrophilic polymer to a surface of a hydrophobic polymer, or a surface obtained by chemically treating, plasma-treating, or radiation-treating a surface of a hydrophobic polymer may be used.
- hydrophilic As the active component, it is preferable to use a hydrophilic polymer such as polyalkylene oxide such as polyethylene glycol, polybutylpyrrolidone, polybutyl alcohol, and polyhydroxyethyl methacrylate.
- a hydrophilic polymer such as polyalkylene oxide such as polyethylene glycol, polybutylpyrrolidone, polybutyl alcohol, and polyhydroxyethyl methacrylate.
- hydrophobic substrate one using a hydrophobic substance or one having a hydrophobic ligand introduced on the surface is used.
- the hydrophobic component include methacrylic acid esters, acrylic acid esters, ethylene such as olefins such as propylene, acrylonitrile, methacrylonitrile, and other compounds having a carbon-carbon double bond, and polymers such as polysulfone and cellulose. Can be exemplified.
- a material on which at least one of the compounds having benzyl group, phenyl group, chloromethyl group, octyl group, lauryl group, etc. for example, ethanol, isopropyl alcohol, amidomethylated polystyrene
- a porous membrane having a form such as a flat membrane or a hollow fiber membrane and having a molecular sieving effect.
- a hollow fiber membrane is effective because the surface area of the separation membrane becomes extremely large.
- the material of the membrane preferably used in this step is not particularly limited, but includes cellulose, a cellulose-based polymer such as cellulose triacetate, a polysulfone-based polymer such as polycarbonate, polysnoreon and polyethersulfone, and polymethyl methacrylate. Polymers of any one of the following materials are used: polymethacrylate, polyacrylate, polyamide nylon, polyvinylidene fluoride, polyacrylonitrile, polyester, polyethylene and polypropylene.
- polysulfone which is often used in dialysers in recent years, has a large ratio of a low-molecular-weight substance to a high-molecular-weight substance and a large coefficient among substances having different molecular weights to be sieved. It is a preferred material because of its good fractionation characteristics.
- the film structure any of those having a sponge structure close to a uniform structure and those having an asymmetric structure in which a dense layer and a thick supporting layer provided to maintain film strength with a high porosity and a multilayer structure have a multilayer structure force can be used. Can also be used.
- Asymmetric structure The preferred method of the recognition method and the asymmetric structure is the same as that described in the first invention group.
- the membrane used in the fractionation step includes a hydrophilic membrane and a hydrophobic membrane in terms of the properties of the membrane surface.
- the hydrophilic film is obtained by copolymerizing a hydrophilic monomer and a hydrophobic monomer, by blending a hydrophilic polymer and a hydrophobic polymer, or by forming a hydrophobic film.
- a hydrophilic polymer bonded to and adhered to the surface of a film made of a high molecular weight polymer, or a film obtained by chemically, plasma or radiation treating the surface of a hydrophobic high molecular weight film.
- the hydrophilic component is not particularly limited, but is preferably a hydrophilic polymer such as polyalkylene oxide such as polyethylene glycol, polybutylpyrrolidone, polybutyl alcohol, and polyhydroxyethyl methacrylate.
- the hydrophobic membrane is not particularly limited as long as it can be used as a membrane material.
- the membrane include a membrane in which a hydrophobic component is mixed and a membrane in which a hydrophobic ligand is introduced.
- the hydrophobic component include olefins such as methacrylic acid esters, acrylic acid esters, ethylene, and propylene, and addition-polymerizable compounds having a carbon-carbon double bond such as acrylonitrile, methacrylic acid-tolyl, and poly-bolylidene. Examples thereof include polymers having physical properties and polymers such as polysulfone and cellulose. .
- a molecular fractionation ability that does not allow albumin to pass through physiological saline for example, a cutoff value of 50 kDa or less, more preferably 30 kDa or less is preferably used.
- various chemicals can be added to the aqueous solution to be charged to improve the adsorption or fractionation performance.
- a suitable amount of ammonium sulfate, polyethylene glycol, poetyleneimine, chaotropic salt, or the like that promotes aggregation of albumin is added to aggregate the protein of the high molecular component to promote macromolecularization.
- a surfactant such as the amphoteric surfactant / anionic surfactant, the interaction between proteins can be suppressed, and the fractionation by molecular sieve can be performed efficiently.
- the step of concentrating means a step of concentrating the protein in the solution.
- concentration step not only the neutral water in the aqueous solution is removed, but also a low molecular component having a molecular weight of lkDa or less may be removed.
- a porous membrane is used for the membrane of the flat filter or the hollow fiber module, and the membrane is concentrated by a separation sieve.
- the membrane used in this step is different from the separation membrane used in the above-mentioned fractionation step (2).
- the liquid permeated through the membrane is used as a desired solution, but in the concentration step (3), the liquid remaining without permeating the membrane is used. Is different in that the desired liquid is obtained.
- the material of the separation membrane that can be used in the concentration step is not particularly limited. Lylic acid ester, polyacrylic acid ester, polyamide, polyvinylidene fluoride, polyacrylonitrile, polyester, polyurethane, polystyrene, polyethylene, polypropylene A polymer of one or the other material is used.
- polysulfone which is often used in dialysis machines in recent years, has good fractionation characteristics (i.e., sieves! /, Among substances of different molecular weights to be separated, sieves of low molecular weight substances relative to high molecular weight substances!). /, The coefficient ratio is large).
- a structure with a sponge structure close to a uniform structure, or a multilayer structure with a dense layer and a thick support layer provided to maintain film strength with a high porosity and asymmetric structure Any of them can be used.
- the method of identifying the asymmetric structure and the preferred embodiment are the same as those described in the first invention group.
- the molecular fractionation ability of a membrane that does not allow passage of the peptide in physiological saline that is, a cutoff value of 0.5 kDa or less, and further 0.015 kDa or less.
- each step are connected by a solution flow path and can be operated continuously, so that an effect that simple and automatic continuous operation can be obtained is obtained.
- each step can be operated independently.
- the liquid may be sent by a syringe.
- concentration is performed by a centrifugal tube type device without using a separation membrane, centrifugation may be performed.
- one step is a certain force (1) a step of adsorbing a protein having a molecular weight of albumin or more, and (2) a protein having a molecular weight of albumin or more is fractionated by molecular sieve. If the step has two or more functions selected from the step of partially or entirely removing the protein and the step (3) of concentrating the protein, it is also possible to carry out the step two or more times. Included in the range.
- the apparatus of the third group of the invention as one means, there are (1) means for adsorbing proteins having a molecular weight of at least albumin, and (2) fractionation of proteins having a molecular weight of at least albumin by molecular sieve. Means for partially or wholly removing and (3) Means for concentrating proteins. If the means has two or more functions, the scope of the present invention in which two or more of these means can be connected to the apparatus is also effective. include.
- steps (1) and (3) can be further repeated by repeating the same steps to further increase the total protein.
- the ratio of albumin to mass is reduced, and an excellent effect of increasing the ratio of low molecular weight proteins to be analyzed can be obtained.
- the decision to repeat the same step or to use two different steps can be designed according to the degree of composition of the protein contained in the biological component initially supplied.
- the power depending on the protein composition in the plasma in the case of healthy adult plasma, the power depending on the protein composition in the plasma.
- a high molecular weight protein having a molecular weight of 50 kDa or more can be obtained.
- the removal rate of 90% or more, the average recovery rate of proteins with a molecular weight of less than 50 kDa is 70% or more, and the average enrichment rate of proteins with a molecular weight of less than 50 kDa is 10 times or more.
- one processing time can be made within 116 hours.
- the present invention relates to a biological component-containing aqueous solution and a biological component-containing solution, particularly from human plasma, urine, saliva, tears, cerebrospinal fluid, ascites, pleural effusion and the like.
- a biological component-containing aqueous solution and a biological component-containing solution particularly from human plasma, urine, saliva, tears, cerebrospinal fluid, ascites, pleural effusion and the like.
- the size of the membrane and the hollow fiber module and the flow rate of the liquid shown in the above are appropriately determined depending on the quality and quantity of the biomaterial such as plasma or urine as a raw material.
- the reaction is performed at a pressure of 1 to 400 mL, preferably 5 to 100 mL, and a flow rate of 11 to 20 mLZmin, preferably 2 to 10 mLZmin.
- FIG. 5 is a conceptual diagram showing an example of an apparatus belonging to the group of the third invention, and is an example of three steps in the order of adsorption, fractionation, and concentration.
- the liquid flow is indicated by arrows.
- a sample of a material such as serum, or a biological component-containing aqueous solution containing the same is passed through a pump 8 for injection and a valve 1 to be a first step module having any of the functions of adsorption, fractionation, and concentration.
- the solution is injected into the module 5 and is pumped through the solution circulation circuit 2 which also has a tube force by the pump 3 and circulates.
- the solution obtained in the first step is obtained in an amount of 4 treatment solutions.
- This embodiment is a unit of one process.
- FIG. 5 shows an example of three stages, in which the module 6 in the second step and the module 7 in the third step are connected.
- the obtained solution is injected into the module of the next step by a tube connected to the processing liquid recovery port.
- the outlet of the step that is, the recovery port of the treatment liquid
- the outlet of the step in the case of the adsorption step is in the middle of the solution circulation circuit.
- the outlet provided therein is provided.
- the outlet in the concentration step is an outlet provided in the middle of the solution circulation circuit.
- each circulation pump has a force provided downstream of each step.
- the circulation pump may be provided upstream of each step.
- the processing of each step can be performed at the same time, and the processing conventionally performed separately for a long time is performed in a short time. This comes out.
- a separation membrane module incorporating a separation membrane is prepared, and a solution circulation circuit is formed by connecting a stock solution (human serum) side inlet and a stock solution (human serum) outlet with a tube.
- a sampling port, a switching valve that can discard the solution without circulating it, and an inflow path that allows the solution to flow into the solution circulation circuit are also provided in the direction of the stock solution side inlet with the stock solution outlet force.
- a pump for circulating the undiluted solution, and a sampling port are provided in order.
- a tube is connected from the filtration side outlet of the module, and a pump for performing filtration and an outlet (sampling port) for the filtered liquid are provided in order.
- the separation membrane module is filled with an aqueous solution of PBS (Dulbecco PBS (-) manufactured by Nippon Pharmaceutical Co., Ltd.) (hereinafter, this aqueous solution is simply referred to as “PBS”) through the inlet channel.
- PBS Denbecco PBS
- the human serum is filtered from the stock solution inlet at 20 ° C at a flow rate of 1 mlZmin and a flow rate of 0.2 mlZmin. Start over.
- the undiluted solution at the module outlet is discarded without returning by switching the valve for discarding the solution in the middle of the solution circulation circuit.
- albumin concentration in this example was performed by outsourcing to SRL, Inc., and was measured using item code 07214 (latex agglutination immunoassay). In this measurement, those whose albumin concentration was below the measurement limit of 0.4 mg / L or less were measured using the BETHYL Human Albumin ELISA Quantitation Kit (Cat No E80-129). ⁇ 2-microglobulin concentration was measured by subcontracting to SRL Co., Ltd. and using item code 02103 (latex agglutination immunoassay).
- the original biological component-containing solution and the “solution with a changed biological component composition” obtained by the method of the present invention were analyzed by two-dimensional electrophoresis.
- the method is as follows.
- electrophoresis buffer for SDS-PAGE (hereinafter referred to as electrophoresis buffer) was composed of 3.0 g of Tris, 14.4 g of glycine, and 1000 ml of distilled water added to 1.0 g of SDS.
- step 13 Transfer the gel piece from step 9 to the second dimension SDS-PAGEmini well, taking care not to introduce air bubbles.
- the small pail is lubricated with a rainbow marker (Amersham), a commercially available molecular weight marker.
- the discharged membrane-forming solution passes through a distance of 350 mm from the spinneret to the liquid surface of the coagulation bath, and is led to a coagulation bath of 100% water, and the hollow fiber membrane was gotten.
- the structure of the obtained hollow fiber membrane was confirmed with an electron microscope (S800, manufactured by Hitachi, Ltd.), it had an asymmetric structure.
- 10,000 hollow fiber membranes obtained were inserted into a cylindrical plastic case having a dialysate inlet and a dialysate outlet in the same manner as a general dialyzer, and both ends were sealed with resin to obtain an effective membrane area. 1.
- a 6 m2 hollow fiber membrane module was made. After the hollow fiber membrane module was washed with water, the module was filled with water and irradiated with ⁇ -rays in a state of being filled. The gamma ray absorbed dose of the module was 27 kGy.
- the hollow fiber membranes of the module were cut out, 100 were bundled, and both ends were fixed to the glass tube module case with an epoxy potting agent so that the hollow portion of the hollow fiber membrane was not closed. Created.
- the mini-module has an outer diameter of about 7 mm and an overall length of about 17 cm, and has two hollow fiber outer ports similar to a general hollow fiber membrane dialyzer.
- the hollow fiber membrane of the mini-module and the inside of the module were washed with distilled water.
- mini-module (1) a hollow fiber membrane mini-module (hereinafter abbreviated as mini-module (1)). Two mini-modules were prepared, and one of them was used to measure the permeation ratio of the separation membrane, which was 70.5. The remaining one was used for the following experiment.
- Human serum (SIGMA H1388, Lot 28H8550) was centrifuged at 3000 rpm for 5 minutes to remove precipitates, and then subjected to a 0.45 ⁇ m filter treatment.
- One of the ports on the outside of the mini-module (1) was capped, and the other was connected with a silicone tube and connected to a peristaltic peristaltic pump.
- the stock solution inlet and the stock solution outlet were connected by a silicone tube to form a solution circulation circuit, and serum could be circulated using a peristaltic pump.
- an inlet for introducing additional PBS was provided in the middle of the solution circulation circuit.
- the total protein in the solution was measured using Micro BCA Protein Assay (manufactured by PIERCE), and the calibration curve was measured using BSA.
- the total protein concentration in the filtrate was 275 mgZl, and the albumin concentration relative to the total protein concentration was 0.22. Further, the concentration of ⁇ 2-microglobulin relative to the total protein was 0.000024 in human serum and 0.000024 in the filtrate, indicating a 10.8-fold increase in calories.
- the discharged membrane-forming solution passed through a distance of 350 mm from the spinneret to the liquid surface of the coagulating bath, and was guided to a coagulating bath of 100% water, and a hollow fiber membrane was obtained.
- a hollow fiber membrane was obtained.
- an electron microscope S800, manufactured by Hitachi, Ltd.
- 10,000 hollow fiber membranes obtained were inserted into a cylindrical plastic case having a dialysate inlet and a dialysate outlet in the same manner as a general dialyzer, and both ends were sealed with resin to obtain an effective membrane area. 1.
- a 6 m2 hollow fiber membrane module was made.
- aqueous solution containing 0.1% by weight of polyethyleneimine (a weight-average molecular weight of 100,000, manufactured by BASF) as a cationic hydrophilic polymer is filled into the hollow fiber membrane module inside and outside the hollow fiber membrane module. did. Thereafter, the module was irradiated with gamma rays. The ⁇ -ray absorption dose of the module was 27 kGy.
- the hollow fiber membranes of the module were cut out, bundled into 100 pieces, and both ends were fixed to a glass tube module case with an epoxy potting agent so as not to close the hollow portion of the hollow fiber membrane, thereby producing a mini-module.
- the mini-module has an outer diameter of about 7 mm and an overall length of about 17 cm, and has two ports outside the hollow fiber like a general hollow fiber membrane type dialyzer.
- the hollow fiber membrane and the inside of the module were washed with distilled water. So Thereafter, an aqueous solution of PBS (Dulbecco PBS (-) manufactured by Nissui Pharmaceutical Co., Ltd.) was filled to obtain a fixed module; a hollow fiber membrane mini-module (hereinafter abbreviated as mini-module (2)). Two mini-modules were prepared, and one of them was used to measure the permeation ratio of the separation membrane. The remaining mini-modules were used for the following experiments.
- mini-module (1) the same hollow fiber membrane mini-module (mini-module (1)) as in Example 1 was prepared, one of the outer ports of the hollow fiber was capped, and the other was connected to a silicone tube.
- the inlet and outlet of the stock solution were connected by a silicone tube to form a solution circulation circuit, and a peristaltic pump was provided on the way to allow the stock solution to circulate.
- a three-way valve was provided in the middle of the solution circulation circuit, and an injection pump was provided on one side via a tube.
- the mini-module (2) also capped one of the outer ports and connected a silicone tube to the other.
- This mini-module also has a solution circulation circuit for the liquid inside the hollow fiber membrane by connecting the inlet and outlet of the undiluted solution, and a bellister pump is provided on the way to allow the solution to circulate.
- a three-way valve was provided in the middle of the solution circulation circuit.
- the silicone tube connected to the port on the outside of the mini-module (1) was joined to a three-way valve provided in the middle of the solution circulation circuit of the mini-module (2). Then, PBS was filled into these tubes and the two modules, and a system was constructed in which two mini modules were connected in series as shown in Fig. 2.
- the mini-module (1) is used to fractionate proteins with a molecular weight higher than albumin
- the mini-module (2) is used to adsorb proteins with a molecular weight higher than albumin and the molecular weight higher than albumin. This corresponds to a step having both functions of fractionating a protein.
- Serum is injected through a tube through an injection pump, and the mini-module (1) and the mini-module (2) are circulated at a flow rate of 5 mlZmin and a filtration flow of 0.2 mlLZmin at 20 ° C in each of the miniature module (1) and minimodule (2). Filtration was performed for 4 hours. At this time, PBS in an amount equal to the volume of the filtered solution was added through an injection pump to keep the circulating liquid amount constant.
- the filtrate obtained from module (2) that is, the solution in which the composition of the biological component has changed, has an albumin concentration of 0.62 mgZL, a1 microglobulin concentration of 0.036 mg / L, and j82 microglobulin The concentration was 0.05 mg ZL.
- the total protein concentration in the human serum used was 53000 mg / l, albumin concentration was 33000 mg / l, a1 microglobulin concentration was 16.5 mgZl, and j82 microglobulin concentration was 1.17 mgZl, indicating significant increase in albumin concentration. Significant decrease was observed.
- the total protein concentration in the filtrate was 8.1 mgZl, and the ratio of albumin concentration to total protein concentration was 0.08.
- the concentration of j82 microglobulin relative to the total protein was 0.000723 in the filtrate compared to 0.000223 in human serum, and the calorie increased 277 times.
- FIG. 7 shows the result of analyzing this sample by two-dimensional electrophoresis.
- FIG. 7 is a two-dimensional electrophoresis photograph of the concentrated solution obtained using 3000 ⁇ l of the solution in which the composition of the biological component was changed, obtained in Example 2. As can be seen from Fig. 7, there are many independent spots at locations with a molecular weight of less than 60,000. The sample separated by this device was able to obtain many spots in the low molecular weight region.
- FIG. 8 is a two-dimensional electrophoresis photograph using 0.5 ⁇ l of human serum before treatment in Example 2.
- the spots are broad, the substance cannot be identified, and spots in the low molecular weight region are hardly observed.
- a resin adhesive portion at both ends of a dialyzer BS1.8L (Lot. 20440312) manufactured by Toray Industries, Inc. was cut to obtain a hollow fiber membrane.
- the dimensions of the obtained hollow fiber membrane were 200 m in inner diameter and 40 m in film thickness.
- the inner diameter of the mini-module is about 5 mm and the length is about 17 cm.
- two ports (blood port) inside the hollow fiber membrane and two ports outside (dialysis fluid) are used. Po Have two).
- the hollow fiber membrane of the mini-module and the inside of the module were washed with distilled water.
- mini-module (3) a hollow fiber membrane mini-module (hereinafter abbreviated as mini-module (3)). Two mini-modules were prepared, and the permeation ratio of the separation membrane was measured using one of them, and it was 149. The remaining one was used for the following experiment.
- Human serum (SIGMA H1388, Lot 122K0424) was centrifuged at 3000 rpm for 5 minutes to remove precipitates, and then filtered at 0.45 ⁇ m.
- the lower port 106 of the module was capped, and the upper port was the processing liquid recovery port 104 of the membrane separation unit.
- the liquid inside the hollow fiber membrane was connected to a stock solution inlet and outlet with a silicone tube to form a solution circulation circuit 102, and a circulation pump 103 as a peristal pump was provided on the way to enable serum to circulate.
- a three-way valve 101 was provided in the middle of the solution circulation circuit 102, and an injection pump was installed on one side of the three-way valve 101.
- the total protein concentration in human serum was 48000 mg / l, albumin concentration was 29800 mg / L, a1 microglobulin concentration was 13.2 mgZL, and j82 microglobulin concentration was 1.27 mgZL.
- Human serum used as stock solution total protein mass used 192,000 / zg, anolebumin amount 119000 g, a1-microglobulin 52.8 / zg, j82 microglobulin amount 5.08 / zg
- the total amount of protein in the filtrate was 56000 ⁇ g
- the amount of albumin was 1640 g
- j82-microglobulin was 3.40 / zg
- the amount of j82-microglobulin Albumin was significantly removed while maintaining the globulin level.
- composition ratio of albumin to the total protein concentration was 0.15.
- composition ratio of ⁇ 2 -microglobulin to the total protein was 0.00000265 in human serum, but 0 in the filtrate. 00613, which was 23 times more calorie.
- mini-module Using the hollow fiber membrane (permeation ratio: 149) obtained in Example 3, one mini-module was prepared.
- the shape of the mini-module and the number of hollow fiber membranes are the same as in Example 3.
- This mini-module is hereinafter referred to as mini-module (4).
- 40 hollow fiber membranes (permeation ratio: 149) obtained in Example 3 were fixed in a glass tube module case having an inner diameter of about 5 mm and a length of about 12 cm. 5) was created in the same manner as in Example 1. These mini-modules were used in the following experiments.
- one mini module (4) was prepared, one of the outer ports was capped, and the other was connected with a silicone tube.
- the stock solution inlet and outlet were connected by a silicone tube to form a solution circulation circuit, and a peristaltic pump was provided in the circuit to allow the solution to circulate.
- a three-way valve was provided in the middle of the solution circulation circuit, and an injection pump was attached in one direction of the three-way valve. This was used as the first-stage membrane separation unit.
- one of the mini-modules (5) was capped on one of the outer ports and connected to a silicone tube on the other.
- a liquid circulation circuit is established by connecting the undiluted solution inlet and outlet of the module with a silicone tube so that a peristaltic pump can be installed in the circuit to circulate the solution. did. Further, a three-way valve was provided in the solution circulation circuit. This was used as the second-stage membrane separation unit. In addition, one of the outer ports of the other mini-module (5) was capped, and one of the remaining ports was connected to a silicone tube.
- FIG. 3 is a schematic diagram of the separation system used in this example.
- the liquid flow is indicated by arrows.
- Serum and diluent (PBS) enter the solution circulation circuit 102 from the infusion pump 100 via the three-way valve 101, and are further sent by the circulation circulation pump 103.
- the first separation membrane module 105 mini module ( 4) is injected into) and circulates through the solution circulation circuit 102.
- the solution obtained in the first membrane separation unit is taken out from the processing liquid recovery port 104 of the membrane separation unit.
- this solution flows into the second-stage separation membrane unit, is injected into the second-stage separation membrane module 205 (the first mini-module (5)), and is further supplied to the second-stage solution circulation circuit 202. Circulated by the second stage circulation pump 203.
- the solution that has passed through the second-stage separation membrane module 205 of the second membrane separation unit is taken out of the processing liquid recovery port 204. Further, this solution flows into the third separation membrane unit, is injected into the third separation membrane module 304 (second mini-module (5)), and circulates. The solution that has passed through the third separation membrane module is obtained from the treatment liquid recovery port 304.
- the albumin concentration was 0.38 mgZl and the ⁇ 2-microglobulin concentration was 0.583 mgZL.
- the total protein concentration was 49,000 mg / l, albumin concentration was 31200 mg / l, and ⁇ 2-microglobulin concentration was 1.19 mgZL.
- the total protein concentration of human serum used as a stock solution is 19600 0 mu g, albumin weight 124800 ⁇ ⁇ , ⁇ 2- microglobulin amount whereas was 4. 76 mu g, total protein of the filtrate 100 g, albumin content 1.5 g, j82-microglobulin content is 2.3 g.
- the composition ratio of albumin to the total protein concentration was 0.02.
- the concentration of j82-microglobulin relative to the total protein was 0.000724 in human serum, 0.0307 in the base solution, and increased by 1263 times.
- the sample was concentrated using a Sartorius vivaspin500 (3000 MWCO type) until the sample volume reached 1Z10, and the sample buffer (0.5 M Tris-HCl (pH 6.8) 0.5 ml, glycerol 0.4 m, 0.8 ml of 10% SDS, 0.1 ml of 0.1% bromophenol blue, 0.1 ml of distilled water were added to make 10 ml), and 25 1 of the solution heated in boiling water for 3 minutes was added. Analysis was performed by electrophoresis. The results are shown in S3 lane in FIG.
- the module strength of the hollow fiber membrane prepared in Example 1 was cut out before irradiation with ⁇ -rays, and 100 hollow fiber membranes were prepared. It was dried for 24 hours under an atmosphere of 50 ° C and a relative humidity of 13%.
- This hollow fiber membrane was fixed at both ends to a glass tube module case with an epoxy potting agent in the same manner as in Example 4 to produce a mini-module.
- the hollow fiber membrane of the mini-module and the inside of the module were washed with distilled water. Thereafter, an aqueous solution of PBS (Dulbecco PBS (-) manufactured by Nissui Pharmaceutical Co., Ltd.) was filled to obtain a hollow fiber membrane mini-module for concentration (hereinafter, referred to as mini-module (6)).
- PBS Dulbecco PBS (-) manufactured by Nissui Pharmaceutical Co., Ltd.
- one of the ports on the outside of the mini module (6) is capped, and the other is filtrate.
- the stock solution inlet and outlet are connected by a silicone tube to form a solution circulation circuit, and the stock solution can be circulated using a peristaltic pump.
- a three-way valve was provided in the middle of the solution circulation circuit. This was used as a concentration membrane unit.
- a separation system having a three-stage membrane separation unit used in Example 4 was newly created.
- the processing liquid recovery port of the third stage mini-module and the three-way knob of the concentration membrane unit were joined with a silicone tube.
- a processing liquid recovery port of the concentration unit which also has a three-way valve, so that only the solution circulation circuit is opened during the concentration operation.
- the entire system was filled with PBS, and a combined system was created in which a membrane separation unit for separating proteins above albumin by molecular sieve and a unit for concentrating proteins were directly connected.
- FIG. 4 is a schematic diagram (an example of a membrane separation unit and a concentration unit) of the separation system used in the fifth embodiment.
- the liquid flow is indicated by arrows.
- Serum and diluent (PBS) are injected into the solution circulation circuit 102 via the injection pump 100 and the three-way valve 101, and further sent by the circulation pump 103, and the first separation membrane module 105 (mini module ( 4) Injected in (1) and circulates through the solution circulation circuit 102.
- the solution treated in the first membrane separation unit is obtained from the treatment liquid recovery port 104 of the membrane separation membrane unit.
- this solution is injected into the second separation module 205 (the first mini-module (5)), and circulates in the second-stage circulation circuit 202.
- the solution treated in the second membrane separation unit is obtained from the treatment liquid recovery port 204 of the second stage membrane separation unit. Further, this solution is injected into the third separation membrane module 305 (second mini-module (5)), and circulates through the third-stage solution circulation circuit 302. The liquid processed by the third membrane separation unit is obtained from the processing liquid recovery port 304. Further, this processing solution is injected into the concentration membrane module 405 (mini-module (6)) and circulates through the concentration unit circulation circuit 402. At this time, the liquid that has passed through the condensing membrane module is taken out from the filtrate outlet 404 of the condensing unit and discarded. After the operation of permeation and concentration is completed, the solution remaining in the circulation circuit 402 of the concentration membrane module is taken out by opening the treatment liquid recovery port 407 of the concentration unit.
- the specific conditions are as follows. 1 ml of serum at 0.2 ml Zmin for first stage membrane separation After adding to the units, the first, second, and third membrane separation units flow through each solution circulation circuit at a flow rate of 5.OmLZmin. Filtration was performed at a flow rate of 0.2 mL Zmin at 20 ° C for 4 hours. At this time, the filtered volume of PBS was added at 0.2 mlZmin from the injection pump 100 to keep the amount of liquid circulating in each separation tube and the concentration unit constant.
- the solution taken out from the valve 407 had an albumin concentration of 0.490 mg Zl, a j82 2-microglobulin concentration of 0.502 mg ZL, and a total protein concentration of human serum used as a stock solution of 49,000 mg. / l, albumin concentration was 31200 mg / L, and 2-microglobulin concentration was 1.19 mg ZL.
- Tsutano der 76 mu g, filtrate is 3.
- the amount of albumin 1 The amount of 81 g and ⁇ 2-microglobulin was 1.86 g, and albumin was significantly removed while maintaining the amount of j82-microglobulin. From these results, the composition ratio of albumin to the total protein concentration was 0.0297. The concentration of j82-microglobulin relative to the total protein was 0.003043 in human serum, 0.0304 in the control solution, and increased by 1253 times.
- the albumin concentration was 5755mgZl, the j82-microglobulin concentration was 0.534mgZl, the albumin concentration in the human serum used as the stock solution was 128.5mgZl, and the j822-microglobulin concentration was 0.446mgZl.
- the human serum used as the stock solution had an albumin content of 27049 g and a ⁇ 2-microglobulin amount of 2.51 ⁇ g, whereas the filtrate had an albumin amount of 578 Ug and a ⁇ 2-microglobulin amount of 2. 01 ⁇ g.
- ⁇ 2-microglobulin, anolevumin and transmission ratio (here, the transmittance is the value obtained by dividing the concentration of the filtrate by the concentration of the stock solution, and the transmission ratio is the value obtained by dividing the transmittance of ⁇ 2-microglobulin by the transmittance of albumin. ) was as low as 40.
- the composition ratio of albumin was as high as 0.32.
- Example 6 A composite system similar to that of Example 5 was created except that the hollow fiber membrane used in the mini-module (2) of Example 2 was used instead of the hollow fiber membrane built in the mini-module (6) of Example 5. .
- the amount of j82-microglobulin was 2.0 ⁇ g, and albumin could be significantly removed while maintaining the amount of ⁇ 2-microglobulin. From these results, the composition ratio of albumin to the total protein concentration was 0.02. Also, the concentration of j82-microglobulin relative to the total protein was 0.00343 in human serum, 0.0343 in the filtrate, and increased by 1414 times.
- the method or the adjusting device of the present invention it is possible to obtain a solution containing a biological component with improved analysis accuracy, and this solution is suitable as a sample for drug research and proteome analysis in clinical settings.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Sustainable Development (AREA)
- Manufacturing & Machinery (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Peptides Or Proteins (AREA)
- Sampling And Sample Adjustment (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04787627A EP1661906B1 (en) | 2003-09-05 | 2004-09-06 | Method of preparing solution for proteomic analysis |
AT04787627T ATE540050T1 (de) | 2003-09-05 | 2004-09-06 | Verfahren zur herstellung einer proteomanalyse- lösung |
JP2005514016A JPWO2005028500A1 (ja) | 2003-09-05 | 2004-09-06 | 生体成分の組成が変化した溶液の調整方法 |
US10/570,488 US20070082401A1 (en) | 2003-09-05 | 2004-09-06 | Method of preparing solution having composition of biological components |
ES04787627T ES2380538T3 (es) | 2003-09-05 | 2004-09-06 | Método de preparación de una solución para análisis proteómico |
CA2537209A CA2537209C (en) | 2003-09-05 | 2004-09-06 | Method of preparing solution having composition of biological components |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003313567 | 2003-09-05 | ||
JP2003-313567 | 2003-09-05 | ||
JP2004-013257 | 2004-01-21 | ||
JP2004013257 | 2004-01-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005028500A1 true WO2005028500A1 (ja) | 2005-03-31 |
Family
ID=34380293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/012923 WO2005028500A1 (ja) | 2003-09-05 | 2004-09-06 | 生体成分の組成が変化した溶液の調整方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070082401A1 (ja) |
EP (1) | EP1661906B1 (ja) |
JP (1) | JPWO2005028500A1 (ja) |
KR (1) | KR20060085238A (ja) |
AT (1) | ATE540050T1 (ja) |
CA (1) | CA2537209C (ja) |
ES (1) | ES2380538T3 (ja) |
WO (1) | WO2005028500A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10112000B2 (en) | 2010-07-08 | 2018-10-30 | Asahi Kasei Medical Co., Ltd. | Method for reducing amyloid beta concentration in blood |
WO2020203716A1 (ja) * | 2019-03-29 | 2020-10-08 | 旭化成メディカル株式会社 | 多孔質膜 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202010151SA (en) * | 2018-05-24 | 2020-11-27 | Toray Industries | Porous hollow fiber membrane |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6422259A (en) * | 1987-07-17 | 1989-01-25 | Ube Industries | Plasma collecting apparatus |
JPH01230370A (ja) * | 1988-12-28 | 1989-09-13 | Kanegafuchi Chem Ind Co Ltd | 血液処理装置 |
WO2001072844A2 (en) * | 2000-03-30 | 2001-10-04 | Amersham Biosciences Ab | A METHOD OF PRODUCING IgG |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4789482A (en) * | 1986-02-10 | 1988-12-06 | Millipore Corporation | Method for separating liquid compositions on the basis of molecular weight |
JPH01299610A (ja) * | 1988-05-28 | 1989-12-04 | Nikkiso Co Ltd | 半透膜およびその製造方法 |
US5492834A (en) * | 1993-07-09 | 1996-02-20 | Beckman Instruments, Inc. | Method of sample preparation for urine protein analysis with capillary electrophoresis |
EP0750938B1 (en) * | 1995-06-30 | 2005-02-16 | Toray Industries, Inc. | Manufacture of a polysulfone hollow fiber semipermeable membrane |
JPH1057476A (ja) * | 1996-08-26 | 1998-03-03 | Toray Ind Inc | 膜分離装置 |
AUPP971399A0 (en) * | 1999-04-12 | 1999-05-06 | Life Therapeutics Limited | Separation of plasma components |
DE10021737C2 (de) * | 2000-05-04 | 2002-10-17 | Hermann Haller | Verfahren und Vorrichtung zur qualitativen und/oder quantitativen Bestimmung eines Protein- und/oder Peptidmusters einer Flüssigkeitsprobe, die dem menschlichen oder tierischen Körper entnommen wird |
JP4214750B2 (ja) * | 2001-10-04 | 2009-01-28 | 東レ株式会社 | 材料およびそれを用いた血液浄化用モジュール |
-
2004
- 2004-09-06 WO PCT/JP2004/012923 patent/WO2005028500A1/ja active Application Filing
- 2004-09-06 JP JP2005514016A patent/JPWO2005028500A1/ja active Pending
- 2004-09-06 US US10/570,488 patent/US20070082401A1/en not_active Abandoned
- 2004-09-06 ES ES04787627T patent/ES2380538T3/es active Active
- 2004-09-06 EP EP04787627A patent/EP1661906B1/en not_active Not-in-force
- 2004-09-06 CA CA2537209A patent/CA2537209C/en not_active Expired - Fee Related
- 2004-09-06 KR KR1020067004448A patent/KR20060085238A/ko not_active Application Discontinuation
- 2004-09-06 AT AT04787627T patent/ATE540050T1/de active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6422259A (en) * | 1987-07-17 | 1989-01-25 | Ube Industries | Plasma collecting apparatus |
JPH01230370A (ja) * | 1988-12-28 | 1989-09-13 | Kanegafuchi Chem Ind Co Ltd | 血液処理装置 |
WO2001072844A2 (en) * | 2000-03-30 | 2001-10-04 | Amersham Biosciences Ab | A METHOD OF PRODUCING IgG |
Non-Patent Citations (2)
Title |
---|
AHMED N. ET AL.: "An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum", PROTEOMICS, vol. 3, no. 10, 23 June 2003 (2003-06-23), pages 1980 - 1987, XP002986338 * |
ROTHEMUND D.L. ET AL.: "Depletion of the highly abundant protein albumin from uman plasma using the gradiflow", PROTEOMICS, vol. 3, no. 3, March 2003 (2003-03-01), pages 279 - 287, XP002986339 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10112000B2 (en) | 2010-07-08 | 2018-10-30 | Asahi Kasei Medical Co., Ltd. | Method for reducing amyloid beta concentration in blood |
WO2020203716A1 (ja) * | 2019-03-29 | 2020-10-08 | 旭化成メディカル株式会社 | 多孔質膜 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005028500A1 (ja) | 2008-03-06 |
KR20060085238A (ko) | 2006-07-26 |
CA2537209A1 (en) | 2005-03-31 |
CA2537209C (en) | 2013-05-14 |
US20070082401A1 (en) | 2007-04-12 |
ATE540050T1 (de) | 2012-01-15 |
EP1661906A4 (en) | 2006-09-06 |
ES2380538T3 (es) | 2012-05-16 |
EP1661906A1 (en) | 2006-05-31 |
EP1661906A9 (en) | 2006-10-04 |
EP1661906B1 (en) | 2012-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4655938B2 (ja) | 分画装置および分画方法 | |
US20110009503A1 (en) | Fractionation apparatus | |
JP2006343220A (ja) | 生体成分含有溶液の前処理方法および分析溶液精製方法 | |
JP2008082728A (ja) | 生体成分分画方法および分画装置 | |
WO2005028500A1 (ja) | 生体成分の組成が変化した溶液の調整方法 | |
JP2005156249A (ja) | 生体成分分離溶液 | |
JP4892824B2 (ja) | 中空糸膜型分離膜の製造方法ならびにその製造方法で製造された中空糸膜型分離膜の使用方法 | |
JP2006256995A (ja) | 生体成分精製溶液、生体成分分離方法および生体成分分離装置 | |
JP2005232156A (ja) | 生体成分精製溶液、生体成分分離方法および生体成分分離装置 | |
JP2005320322A (ja) | 分画装置 | |
JP2005214919A (ja) | タンパク質および/もしくはペプチド分析前処理用分離膜 | |
JP2005126376A (ja) | 生体成分精製溶液 | |
JP2007003213A (ja) | 生体成分含有溶液の分離精製システムおよび分離精製方法 | |
CN100451031C (zh) | 生物体成分组成改变了的溶液的调制方法 | |
JP2006194724A (ja) | タンパク質および/もしくはペプチド分析前処理用分離膜 | |
JP2005177573A (ja) | 分離システム | |
JP2006089468A (ja) | タンパク質分画デバイス用緩衝液およびそれを用いるタンパク質の分画方法 | |
JP2007016016A (ja) | 分画方法および分画装置 | |
JP2006276009A (ja) | タンパク質分画デバイスおよびそれを用いるタンパク質の分画・回収方法 | |
JP2006342154A (ja) | タンパク質分画デバイス | |
JP2006272137A (ja) | 分画装置および分画装置用カートリッジ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480025465.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005514016 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2537209 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067004448 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004787627 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004787627 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067004448 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007082401 Country of ref document: US Ref document number: 10570488 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10570488 Country of ref document: US |